The adiponectin agonist AdipoRon accelerates osteoporosis development in two different models and modulates adipocyte...

Area of Science:

• Endocrinology
• Metabolic Bone Diseases
• Adipocyte Biology

Background:

• Osteoporosis and lipid metabolism disturbances are growing global health concerns.
• Adipocytes and their product adiponectin are implicated in metabolic and cardiovascular health.
• AdipoRon, an adiponectin receptor agonist, was investigated for potential anti-osteoporosis effects.

Purpose of the Study:

• To investigate the effect of AdipoRon on osteoporosis development in preclinical models.
• To explore AdipoRon's impact on adipocyte differentiation and identity.
• To understand AdipoRon's role in glucocorticoid-induced bone loss.

Main Methods:

• Utilized two preclinical models of osteoporosis.
• Administered AdipoRon treatment.
• Analyzed adipocyte differentiation and gene expression.
• Assessed bone marrow adipocyte presence.

Main Results:

• AdipoRon treatment accelerated metabolic changes and bone loss in both models, contrary to expectations.
• AdipoRon rescued bone marrow adipocyte populations diminished by glucocorticoids.
• AdipoRon demonstrated time- and duration-dependent opposing effects on adipocyte gene induction, altering adipocyte identity.

Conclusions:

• AdipoRon's effect on osteoporosis is complex and warrants further investigation.
• Adiponectin signaling may play a dual role in bone metabolism.
• Adipocyte-derived adiponectin is a potential autocrine mediator in musculoskeletal research.